摘要
背景:自噬相关蛋白(ATGs)的免疫组化分析最近被应用于人类病理学研究分化和癌症进展。本研究的目的是通过5种ATG抗血清(Beclin-1、LC3A/B、p62、ULK-1和AMBRA-1)分析胃癌队列,并评估它们与临床病理参数、HER2状态和患者最终结局的可能关系。 方法:用ATG抗血清对123名GCs进行研究,采用Masuda的标准,确定阳性病例,其中至少有2 / 5的蛋白表达被记录。 结果:自噬的免疫组化标志(A-IHC)为49.59%。A-IHC的比例从低粘连癌的31%到腺癌的56%不等。各ATG免疫标记物对LC3A/B、Beclin-1和p62的敏感性、特异性和效率均较高。单因素分析GC、分级、分期、Ki67表达、HER2状态及A-IHC均为高p值(p < 0.001)。最后,在多变量分析中,HER2状态、分期和A-IHC成为独立的预后变量。生存曲线比较中,A-IHC阳性的GC病例生存时间较短,预后较差。 结论:我们假设A-IHC可以作为一种额外的形态学工具来提供预后因素,以识别生存时间较短和预后较差的侵袭性患者。
关键词: 自噬,免疫组化,胃癌,HER2状态,预后,癌症治疗。
[http://dx.doi.org/10.1016/j.cell.2011.10.026] [PMID: 22078875]
[http://dx.doi.org/10.1080/15548627.2017.1378838] [PMID: 28933638]
[http://dx.doi.org/10.1111/tra.12484] [PMID: 28371052]
[http://dx.doi.org/10.1038/s41580-018-0003-4] [PMID: 29618831]
[http://dx.doi.org/10.1016/j.apsb.2019.10.003] [PMID: 32322463]
[http://dx.doi.org/10.2174/1389450117666160622220915] [PMID: 27358060]
[http://dx.doi.org/10.2174/156800911794519707] [PMID: 21247381]
[http://dx.doi.org/10.1016/j.semcancer.2013.06.007] [PMID: 23811268]
[http://dx.doi.org/10.18632/oncotarget.7508] [PMID: 26910278]
[http://dx.doi.org/10.1101/gad.287524.116] [PMID: 27664235]
[http://dx.doi.org/10.1016/j.tcb.2015.11.001] [PMID: 26612212]
[http://dx.doi.org/10.1080/01913123.2017.1388322] [PMID: 29192807]
[http://dx.doi.org/10.3390/cells9041063] [PMID: 32344698]
[http://dx.doi.org/10.3390/cancers12030562] [PMID: 32121322]
[http://dx.doi.org/10.3390/cancers12020352] [PMID: 32033142]
[http://dx.doi.org/10.1186/s12943-020-1138-4] [PMID: 31969156]
[http://dx.doi.org/10.3390/ijms19113466] [PMID: 30400561]
[http://dx.doi.org/10.2174/156652407779940503] [PMID: 17311530]
[http://dx.doi.org/10.3390/ijms19124109] [PMID: 30567376]
[http://dx.doi.org/10.3390/ijms17010109] [PMID: 26784180]
[http://dx.doi.org/10.1111/apm.13034] [PMID: 32352605]
[http://dx.doi.org/10.3390/cells9041055] [PMID: 32340207]
[http://dx.doi.org/10.1136/jclinpath-2011-200345] [PMID: 22067088]
[http://dx.doi.org/10.3892/ol.2013.1611] [PMID: 24260051]
[http://dx.doi.org/10.3390/ijms151222331] [PMID: 25479078]
[http://dx.doi.org/10.1155/2015/234851] [PMID: 26494937]
[http://dx.doi.org/10.1155/2018/1505428] [PMID: 29670669]
[http://dx.doi.org/10.3390/jpm10010010] [PMID: 32098203]
[http://dx.doi.org/10.4161/cbt.11.9.15045] [PMID: 21307659]
[http://dx.doi.org/10.1016/j.critrevonc.2015.08.004] [PMID: 26364890]
[http://dx.doi.org/10.4414/smw.2019.20138] [PMID: 31656036]
[http://dx.doi.org/10.1016/j.canlet.2012.02.017] [PMID: 22542808]
[PMID: 27725863]
[http://dx.doi.org/10.3390/cells6030017] [PMID: 28665306]
[http://dx.doi.org/10.4081/ejh.2015.2481] [PMID: 26150155]
[http://dx.doi.org/10.1038/bjc.2014.355] [PMID: 24983366]
[http://dx.doi.org/10.1016/j.celrep.2020.107547] [PMID: 32320653]
[PMID: 26722036]
[http://dx.doi.org/10.1007/978-3-030-20301-6_5] [PMID: 31456180]
[http://dx.doi.org/10.3389/fphar.2020.00408] [PMID: 32322202]
[http://dx.doi.org/10.1007/s00432-018-2605-9] [PMID: 29435734]
[http://dx.doi.org/10.1007/s13277-014-2060-4] [PMID: 24838948]
[http://dx.doi.org/10.1016/j.prp.2014.11.005] [PMID: 25512258]
[http://dx.doi.org/10.1007/s13277-016-5383-5] [PMID: 27655288]
[PMID: 29422968]
[http://dx.doi.org/10.1080/15548627.2016.1164357] [PMID: 27166522]
[http://dx.doi.org/10.1073/pnas.1717800115] [PMID: 29610308]
[http://dx.doi.org/10.3390/ijms19103069] [PMID: 30297650]
[http://dx.doi.org/10.1634/theoncologist.2017-0379] [PMID: 29700210]
[http://dx.doi.org/10.1158/1535-7163.MCT-19-0455] [PMID: 31484705]